Home > 新闻动态 > 恭喜马珅慧博士后的论文在一区期刊Biosensors and Bioelectronics上发表

近日,本课题组张敏老师和马珅慧博士后分别以通讯作者和第一作者在生物传感器领域国际知名期刊Biosensors and Bioelectronics(SCI一区,2021年IF=10.618)上发表了题为“Tetrahedral DNA nanostructure based biosensor for high-performance detection of circulating tumor DNA using all-carbon nanotube transistor”的文章。


该工作实现了一种基于DNA折纸技术和全碳纳米管薄膜晶体管的新型生物传感器,并研究了该传感器在血液循环肿瘤DNA检测方面的应用。在本工作中我们首次将全碳纳米管薄膜晶体管(all-carbon nanotube thin-film transistor,all-CNT TFT)生物传感器与四面体DNA纳米结构(tetrahedral DNA nanostructures,TDNs)相结合,实现了对三阴性乳腺癌标志物AKT2基因的检测。与传统单链DNA探针相比,采用TDNs的all-CNT TFT生物传感器可实现高达98%的响应提升。该生物传感器实现了具有高选择性和高可重复性的DNA检测,其线性检测范围达到六个数量级,理论检测限可达2fM。该研究提出的all-CNT TFT生物传感器结合TDNs的平台有望实现多种癌症标志物的同时捕获,为临床检测提供一种简单、有效、高性能的通用“液体活检”策略。

Adopting carbon nanotube (CNT) transistors as biosensors has been developed as a promising method for cancer biomarker detection, which has shown superior sensitivity and selectivity. However, the detection of circulating tumor DNA (ctDNA) by the CNT transistor based biosensors is still a challenge and no work has been reported. Here, direct label-free DNA detection of AKT2 gene related to triple-negative breast cancer by all-CNT thin-film transistor (TFT) biosensors incorporated with tetrahedral DNA nanostructures (TDNs) is proposed and achieved for the first time. The adoption of TDNs enables improved biosensor response for at least 35% and even as high as 98% as compared with single-stranded DNA (ssDNA) probes owing to the enhanced DNA hybridization efficiency. Influence of the TDNs’ linker length on the biosensor performance is important and has been investigated. Concentration-dependent DNA detection is achieved by the all-CNT TFT biosensors with a broad linear detection range of six orders of magnitude and a theoretical limit of detection (LOD) of 2 fM. In addition, the all-CNT TFT biosensors exhibit favorable selectivity and repeatability. The platform of all-CNT TFT biosensors incorporated with TDNs has great potential for multiplexed detection of various cancer biomarkers, providing a simple yet high performance universal strategy for low-cost clinical applications.